Toggle light / dark theme

Niraparib Shows Promise in Hard-to-Treat Prostate Cancers

Adding PARP inhibitor niraparib to standard prostate cancer treatment delays disease progression in men with certain DNA repair gene mutations. | Drug Discovery And Development

Leave a Comment

Lifeboat Foundation respects your privacy! Your email address will not be published.

/* */